Month: September 2024

VANCOUVER, British Columbia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) (“MAX Power” or the “Company”) announces the results of its annual…

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.KEY INFORMATION (a)Full name of discloser:Dimensional Fund Advisors…

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.KEY INFORMATION (a)Full name of discloser:Dimensional Fund Advisors…

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.KEY INFORMATION (a)Full name of discloser:Dimensional Fund Advisors…

COMPANY ANNOUNCEMENT no. 68 - 16 September 2024 On 9 February 2024, DFDS A/S (“DFDS”) announced the initiation of a share buyback programme to be executed in accordance with EU…

SELSKABSMEDDELELSE nr. 68 - 16. september 2024 Den 9. februar 2024 meddelte DFDS A/S (“DFDS”) iværksættelsen af et aktietilbage-købsprogram til gennemførsel i henhold til EUs markedsmisbrugsforordning, EU forordning nr. 596/2014…

- Un taux de réponse objective (TRO) cliniquement significatif de 63,3–76,7 % a été observé avec l’association belrestotug + dostarlimab, avec un TRO confirmé (TROc) d'environ 60 % pour chaque…

- Klinisch bedeutsame objektive Ansprechrate (Objective Response Rate, ORR) von 63,3–76,7 % bei der Kombination von Belrestotug + Dostarlimab, mit einer bestätigten ORR (confirmed ORR, cORR) von ca. 60 %…

Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12),…